arrow
V

Victoria Bae-Jump

washington university
H指数:41
被引数:5,933

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

MLH1 promoter hypermethylation and associations with survival outcomes: A real-world endometrial cancer molecularly targeted therapy consortium cohort study

MLH1启动子高甲基化及其与生存结局的关联:一项真实世界子宫内膜癌分子靶向治疗联盟队列研究

2026-07-010
PRE
Stool and vaginal microbiome profiles patterns among Black and White endometrial cancer survivors: A pilot study in North Carolina

黑人子宫内膜癌幸存者与白人子宫内膜癌幸存者粪便和阴道微生物组谱模式:一项在北卡罗来纳州进行的试点研究

2026-01-230
PRE
Molecular characteristics by race and ethnicity of patients with high tumor mutational burden, high microsatellite instability, and mismatch repair deficiency: Real-world data from the multi-institutional Endometrial cancer Molecularly Targeted Therapy Consortium (ECMT2)

高肿瘤突变负荷、高微卫星不稳定性及错配修复缺陷患者的种族和族裔分子特征:多机构子宫内膜癌分子靶向治疗联盟(ECMT2)的真实世界数据

2025-07-110
PRE
Genomic alterations, molecularly targeted therapy, and survival: a real-world Endometrial Cancer Molecularly Targeted Therapy Consortium cohort study

基因组改变、分子靶向治疗与生存:一项真实世界子宫内膜癌分子靶向治疗联盟队列研究

2025-05-010
PRE
A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG oncology/GOG study

一项关于紫杉醇/卡铂/二甲双胍与紫杉醇/卡铂/安慰剂作为可测量病灶的III期或IVA期、IVB期或复发性子宫内膜癌初始治疗方案的比较研究:一项NRG oncology/GOG研究

2025-04-011
OAAI
Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer molecularly targeted therapy consortium cohort study

无铂间期及对复发性子宫内膜癌患者铂类再治疗或lenvatinib/pembrolizumab的应答:一项真实世界子宫内膜癌分子靶向治疗联盟队列研究

2025-03-010
PRE